TP53 P278S

CI-VAR-00003327Explore in graph →NP_000537.3:p.Pro278SerNM_000546.5:c.832C>TClinVar 376642 CIViC 1049 rs17849781

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Skin Squamous Cell Carcinoma1
TP53 P278S	Vemurafenib	Predictive	C	Supports Resistance	—	submitted	EID4419 In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC) PMID 22256804 · Su et al., 2012 · Open in CIViC	civic
Unmapped disease1unmapped disease
TP53 P278S	(functional)	Functional	D	Does Not Support Dominant Negative	3	accepted	EID10233 A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. T… (full text at CIViC) PMID ·

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
376642	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts	2	Ovarian neoplasm; Hereditary cancer-predisposing syndrome; Li-Fraumeni syndrome; Li-Fraumeni syndrome 1; TP53-related disorder; Pleuropulmonary blastoma	germline/somatic	8	Dec 09, 2025	clinvar